Even if it's not a huge purchase, we think it was good to see that Jianxin Yang, the CEO, Senior VP & Chief Medical Officer of CStone Pharmaceuticals (HKG:2616) recently shelled out HK$668k to buy stock, at HK$4.45 per share. However, it only increased their shares held by 2.2%, and it wasn't a huge purchase by absolute value, either.

Check out our latest analysis for CStone Pharmaceuticals

CStone Pharmaceuticals Insider Transactions Over The Last Year

The Senior Advisor, Ningjun Jiang, made the biggest insider sale in the last 12 months. That single transaction was for HK$45m worth of shares at a price of HK$7.57 each. While we don't usually like to see insider selling, it's more concerning if the sales take place at a lower price. The good news is that this large sale was at well above current price of HK$4.21. So it is hard to draw any strong conclusion from it. The only individual insider seller over the last year was Ningjun Jiang.

Ningjun Jiang ditched 7.30m shares over the year. The average price per share was CN¥7.77. You can see the insider transactions (by companies and individuals) over the last year depicted in the chart below. By clicking on the graph below, you can see the precise details of each insider transaction!

If you are like me, then you will not want to miss this free list of growing companies that insiders are buying.

Insider Ownership Of CStone Pharmaceuticals

Many investors like to check how much of a company is owned by insiders. A high insider ownership often makes company leadership more mindful of shareholder interests. It appears that CStone Pharmaceuticals insiders own 1.7% of the company, worth about HK$86m. While this is a strong but not outstanding level of insider ownership, it's enough to indicate some alignment between management and smaller shareholders.

What Might The Insider Transactions At CStone Pharmaceuticals Tell Us?

It is good to see the recent insider purchase. On the other hand the transaction history, over the last year, isn't so positive. We don't take much heart from transactions by CStone Pharmaceuticals insiders over the last year. But they own a reasonable amount of the company, and there was some buying recently. So they seem pretty well aligned, overall. Therefore, you should definitely take a look at this FREE report showing analyst forecasts for CStone Pharmaceuticals.

Of course, you might find a fantastic investment by looking elsewhere. So take a peek at this free list of interesting companies.

For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions, but not derivative transactions.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.